Argenx poised to expand Vyvgart market off new phase 3 data

. @argenx.com has a new edge against rising competition in the #gMG space as new Phase 3 data shows #Vyvgart effective in all AChR-Ab seronegative patients -- a group that has had few to no treatment options up until now. pharmaphorum.com/news/argenx-...

Argenx stock falls after FDA flags serious risk signal with Vyvgart Investing.com -- Argenx NV ADR (NASDAQ:ARGX) stock tumbled 6% after the U.S. Food and Drug Administration (FDA) identified a potential serious risk associated with the company’s lead drug, Vyvgart. The FDA published a report highlighting a "severe worsening of chronic inflammatory demyelinating polyradiculoneuropathy" as a potential signal of serious risk with Vyvgart Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) injection. The regulatory agency stated it is currently evaluating the need for regulatory action. Vyvgart is Argenx’s flagship product, approved for treating generalized myasthenia gravis, a rare autoimmune disease. The identification of this safety concern comes at a critical time for the company, which has been positioning the medication as a key growth driver. The FDA regularly monitors approved drugs for potential safety issues that weren’t identified during clinical trials. When a potential signal is detected, the agency conducts further investigation to determine whether regulatory action is warranted, which could range from label updates to more significant restrictions. Investors reacted to the news by selling shares, reflecting concerns about potential impacts on Vyvgart’s commercial prospects should the FDA determine that additional warnings or limitations are necessary. This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Click Subscribe #Argenx #Vyvgart #FDANews #StockMarket #Investing

Argenx receives positive CHMP opinion for CIDP treatment - PharmaTimes VYVGART could be the first CIDP drug with a novel mechanism in 30 years

#Argenx #CHMP #CIDPtreatment #VYVGART #efgartigimodalfa #chronicinflammatorydemyelinatingpolyneuropathy #CIDPdrug #ADHEREtrial #CIDPclinicalstudy #IgGFcantibodyfragment #immunoglobulintherapy #CIPDpatients #EPODIN #CIPDmanagement #CHMPrecommendation #CHMPopinion
pharmatimes.com/news/argenx-...

Halozyme Secures FDA Approval for VYVGART® Hytrulo Prefilled Syringe Targeted at Myasthenia Gravis Patients Halozyme has announced that argenx received FDA approval for VYVGART® Hytrulo prefilled syringe, enhancing treatment options for myasthenia gravis and CIDP patients.

Halozyme Secures FDA Approval for VYVGART® Hytrulo Prefilled Syringe Targeted at Myasthenia Gravis Patients #USA #San_Diego #FDA_Approval #Halozyme #VYVGART

Nobody talks about how scary and emotional #healing is. #myastheniagravis #vyvgart

I'm wearing real shoes for the first time in 2+years for my first PT appointment. I've only been wearing moccasins and slippers. #myastheniagravis #disability #vyvgart

Today is a #CIDP day. Autoimmune disorders are something that people with #chronicillness live with everyday and usually have more than 1. Today is a #Vyvgart ,but #IVIG is another common therapy. It's amazing what #bloodonation and #plasmadonation can do to help others! 🩸👩🏻‍⚕️
youtu.be/WJVVYk1sg0I?...